Hookipa Pharma Inc. has announced an agreement to sell certain assets to Gilead Sciences, Inc. The transaction, dated May 21, 2025, involves the sale of assets primarily related to Hookipa's HB-400 program, which is currently in clinical development for treating hepatitis B virus, as well as certain assets from the HB-500 program, focused on the human immunodeficiency virus. Gilead will pay up to $10 million for these assets, with $3 million due at closing and the remainder contingent on the completion of a three-phase transfer plan. The deal excludes certain assets, such as the Phase 1b clinical trial of HB-500 and other clinical and preclinical programs. Hookipa Pharma is collaborating with Gilead under an existing research collaboration and license agreement.